Engene Holdings INC Schedule 13G passive stakes

Multiple Venrock-affiliated entities have reported a complete divestment of their holdings in enGene Holdings Inc. as of June 30, 2026.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have reported a 0.0% beneficial ownership of enGene Therapeutics Inc. common shares as of June 30, 2026, indicating a complete divestment.

Investment group Invus discloses an increased beneficial ownership of enGene Therapeutics' common shares, now holding 9.3% of the outstanding stock.

Blue Owl Capital Holdings LP has disclosed beneficial ownership of 511,177 common shares, representing 0.76% of enGene Therapeutics Inc., acquired via warrants.

Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove have collectively reported beneficial ownership of 5.0% of enGene Therapeutics Inc. common shares.

Cormorant Asset Management, LP and Bihua Chen have filed a Schedule 13G, reporting no beneficial ownership of enGene Holdings Inc. common shares as of March 31, 2026.

BML Investment Partners, L.P. has disclosed a beneficial ownership of 9.95% of enGene Holdings Inc.'s common shares, as per a Schedule 13G filing.

BML Investment Partners, L.P. has filed a Schedule 13G reporting a 7.8% beneficial ownership stake in enGene Holdings Inc.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 7.8% of enGene Therapeutics Inc. common shares as of March 31, 2026.

Cormorant Asset Management, LP and Bihua Chen have reported a 5.97% beneficial ownership stake in enGene Holdings Inc. common shares.

Kynam Capital Management, LP and affiliates reported a beneficial ownership of 2.23% in enGene Holdings Inc. common shares via an amended Schedule 13G.

Raymond Debbane and affiliated entities, including Invus Public Equities and Avicenna Life Sci Master Fund, reported a combined 6.3% passive beneficial ownership in enGene Holdings Inc.

Deep Track Capital, its biotech fund, and David Kroin reported a passive 6.69% beneficial stake (4.32M shares) in enGene Holdings with shared voting and dispositive power.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a 9.99% beneficial ownership stake in enGene Holdings Inc. common shares.

Deep Track Capital and affiliates have reduced their beneficial ownership in enGene Holdings Inc. to 4.37% of common shares.

A group of Venrock investment entities and affiliated individuals have disclosed a collective beneficial ownership of 9.9% of enGene Holdings Inc.'s Common Shares as of December 31, 2024, according to an amended Schedule 13G filing.

Kynam Capital Management, LP, along with its general partner and managing member, has reported a collective beneficial ownership of 9.8% of enGene Holdings Inc.'s common shares.

Foresite Capital Fund VI, L.P., Foresite Capital Management VI, LLC, and James Tananbaum have filed an amended Schedule 13G, disclosing a complete divestment of their beneficial ownership in enGene Holdings, Inc., now holding 0% of common shares.

Deep Track Capital and its affiliates have reported a beneficial ownership of 8.94% in enGene Holdings Inc., holding 4,557,575 common shares as of December 31, 2024.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has filed an amended Schedule 13G disclosing a 3.00% beneficial ownership stake in enGene Holdings Inc., totaling 1,528,768 common shares as of December 31, 2024.

Multiple entities affiliated with Biotechnology Value Fund have filed an amended Schedule 13G, disclosing beneficial ownership of 945,402 common shares of enGene Holdings Inc. through warrants, representing approximately 1.8% of the outstanding class.

Multiple entities associated with Biotechnology Value Fund, including BVF Partners L.P. and Mark N. Lampert, have disclosed a combined beneficial ownership of 5.9% in enGene Holdings Inc., primarily for passive investment purposes.